Evidence map›Paper›PMID 32813765›Full record

ArticleArchives of endocrinology and metabolism2020

Reference values of 25-hydroxyvitamin D revisited: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC).

Carolina Aguiar Moreira, Carlos Eduardo Dos S Ferreira, Miguel Madeira, Barbara Campolina Carvalho Silva, Sergio Setsuo Maeda, Marcelo Cidade Batista, Francisco Bandeira, Victória Z Cochenski Borba, Marise Lazaretti-Castro

Erratum issuedOpen access · diamondAbstract readConsensus Statement
In one paragraph

Article in Archives of endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Review
  7. Supplements for bone health.Archives of endocrinology and metabolism · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. A view on vitamin D: a pleiotropic factor?Nature reviews. Endocrinology · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Vitamin D metabolism and extraskeletal outcomes: an update.Archives of endocrinology and metabolism · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Carolina Aguiar MoreiraDepartamento de Metabolismo Ósseo, Sociedade Brasileira de Endocrinologia e Metabologia, Brasil.
Carlos Eduardo Dos S FerreiraSociedade Brasileira de Patologia Clínica/Medicina Laboratorial, Brasil.
Miguel MadeiraDepartamento de Metabolismo Ósseo, Sociedade Brasileira de Endocrinologia e Metabologia, Brasil.
Barbara Campolina Carvalho SilvaDepartamento de Metabolismo Ósseo, Sociedade Brasileira de Endocrinologia e Metabologia, Brasil.
Sergio Setsuo MaedaDepartamento de Metabolismo Ósseo, Sociedade Brasileira de Endocrinologia e Metabologia, Brasil.
Marcelo Cidade BatistaSociedade Brasileira de Patologia Clínica/Medicina Laboratorial, Brasil.
Francisco BandeiraDepartamento de Metabolismo Ósseo, Sociedade Brasileira de Endocrinologia e Metabologia, Brasil.
Victória Z Cochenski BorbaDepartamento de Metabolismo Ósseo, Sociedade Brasileira de Endocrinologia e Metabologia, Brasil.
Marise Lazaretti-CastroDepartamento de Metabolismo Ósseo, Sociedade Brasileira de Endocrinologia e Metabologia, Brasil.
Sociedade Brasileira de Oncologia Clínica · BRHospital Israelita Albert Einstein · BRCentro Universitário de Belo Horizonte · BRHospital de Clínicas Universidade Federal do Paraná · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypovitaminosis D is a common condition with a negative impact on health. This statement, prepared by experts from the Brazilian Society of Endocrinology and Metabolism and the Brazilian Society of Clinical Pathology/Laboratory Medicine, includes methodological aspects and limitations of the measurement of 25-hydroxyvitamin D [25(OH)D] for identification of vitamin D status, and identifies individuals at increased risk for deficiency of this vitamin in whom 25(OH)D measurement is recommended. For the general population, 25(OH)D levels between 20 and 60 ng/mL are considered normal, while individuals with levels below 20 ng/mL are considered to be vitamin D deficient. This statement identifies potential benefits of maintaining 25(OH)D levels > 30 ng/mL in specific conditions, including patients aged > 65 years or pregnant, those with recurrent falls, fragility fractures, osteoporosis, secondary hyperparathyroidism, chronic kidney disease, or cancer, and individuals using drugs with the potential to affect the vitamin D metabolism. This statement also calls attention to the risk of vitamin D intoxication, a life-threatening condition that occurs at 25(OH)D levels above 100 ng/mL.

Indexed as

Pathology, ClinicalAgedBrazilHumansReference ValuesVitamin DVitamin D Deficiency25-hydroxyvitamin DVitamin D

Identifiers

PMID32813765
PMCPMC10522078
OpenAlexW3035943097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.